ARTICLE | Clinical News
NGR-hTNF: Completed Phase III enrollment
December 24, 2012 8:00 AM UTC
MolMed completed enrollment of 390 patients who progressed after pemetrexed-based chemotherapy in the double-blind, international Phase III NGR015 trial comparing weekly 0.8 ug/m 2 IV NGR-hTNF plus be...